The Long Run with Luke Timmerman

Ep114: Chris Gibson on Industrializing Drug Discovery

May 23, 2022

01:06:33

Creator website

Highlights

AI Chapters

Episode notes

Is Fibrosis a Good Place for Imaging?

02:55

The Future of Computational Chemistry

02:34

What's the Difference Between Function First and Project First?

02:21

Introduction

4min

The Long Run - Chris Gibson

2min

Macursh - What's Your Story?

2min

What Kind of School Did You Go To?

2min

How Did You Get Interested in Science or Biology?

2min

What Was It About Biology That Captured Your Interest?

2min

How Did You End Up at the University of Texas, Austin?

3min

The University of Texas, a Great Place to Pursue Your Own Thing

4min

The Problem With Penotipic Screens in Pathology

3min

10.

How Did You Get the Funding?

4min

11.

Were You Naive in Those Early Days?

3min

12.

The Future of Computational Chemistry

3min

13.

Accelerate Drug Development With Ai Powered Three D

4min

14.

How Did Genante's Series a Change the Company?

2min

15.

The Industrial Revolution of Drug Discovery

3min

16.

Creating a Virtuous Cycle of Learning and Iteration

3min

17.

Machine Learning Is Changing the Way We Do Business

2min

18.

Pivotal Partnerships in Fibrosis

2min

19.

Is Fibrosis a Good Place for Imaging?

3min

20.

The Partnership With Russia's Genent on Cancer

2min

21.

The Currency of Our Industry Is Not Algarisms

2min

22.

What's the Difference Between Function First and Project First?

2min

23.

The Challenges of Operating in Salt Lake City?

3min

24.

Why Did You Open New Offices in Toronto, Montreal?

2min

25.

Is There a Right or Wrong Shareholder Perspective?

4min

Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.